ACLY and metabolic syndrome: Remarkably, research using bempedoic acid, a dual Ampk activator/Acly inhibitor developed for the treatment of dyslipidemia and cardio-metabolic disease17, has provided positive results in lowering low-density lipoprotein cholesterol in clinical trials, and it is currently in the market18–20.